Source:http://linkedlifedata.com/resource/pubmed/id/18673399
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2009-11-13
|
pubmed:abstractText |
Compared to HIV and hepatitis C virus, the residual infectious risk of hepatitis B virus (HBV) posed by blood products is about 10 times higher. In addition to HBsAg testing, screening for anti-HBc was recommended by the German Advisory Committee Blood in March 2005. Prevalence of anti-HBc in German blood donors was investigated at five test sites located in different geographic regions. In total, 12,000 blood donors were screened for anti-HBc by PRISM HBcore, and a statistically representative number of these were tested with Abbott Murex anti-HBc total, bioMérieux Hepanostika anti-HBc uniform, Bio-Rad Monolisa anti-HBc PLUS and Dade Behring Enzygnost anti-HBc. Anti-HBc repeat reactive samples were tested for anti-HBs, anti-HBe and HBV DNA by individual donation NAT. The mean prevalence of anti-HBc was 1.75% in donors that had not been tested for anti-HBc in the past. The percentage of anti-HBs in anti-HBc repeat reactive donors was 93.7%. Samples that were additionally reactive for anti-HBe were anti-HBc reactive in all tested assays. The sample to cut-off (S/Co) values for anti-HBc were lower (competitive assays) in samples that were also positive for anti-HBe, when compared to samples that were only anti-HBc reactive. Most commercially available anti-HBc assays provide sufficient sensitivity for routine screening purposes, and lacking specificity is no longer a serious issue for most of them. Assay differences were recognized for samples that were anti-HBc only reactive. The overall loss of 1.75% of positive testing donors can be significantly reduced to 0.45% by implementation of re-entry procedures for donors with an anti-HBs titre of over 100 IU/l and negative by sensitive ID-NAT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1751-553X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
649-56
|
pubmed:meshHeading |
pubmed-meshheading:18673399-Blood Donors,
pubmed-meshheading:18673399-Communicable Disease Control,
pubmed-meshheading:18673399-DNA, Viral,
pubmed-meshheading:18673399-Donor Selection,
pubmed-meshheading:18673399-Germany,
pubmed-meshheading:18673399-Hepatitis B,
pubmed-meshheading:18673399-Hepatitis B Antibodies,
pubmed-meshheading:18673399-Hepatitis B Core Antigens,
pubmed-meshheading:18673399-Hepatitis B Surface Antigens,
pubmed-meshheading:18673399-Hepatitis B virus,
pubmed-meshheading:18673399-Humans,
pubmed-meshheading:18673399-Sensitivity and Specificity
|
pubmed:year |
2009
|
pubmed:articleTitle |
Sensitivity and specificity of Anti-HBc screening assays--which assay is best for blood donor screening?
|
pubmed:affiliation |
Institute of Transfusion Medicine and Immunohematology, German Red Cross, Johann Wolfgang Goethe University, Frankfurt, Germany.
|
pubmed:publicationType |
Journal Article
|